BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim SY, Wu EH, Park SH, Wang ZJ, Hope TA, Yee J, Zhao LQ, Chang WC, Yeh BM. Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent. Abdom Radiol (NY) 2016;41:1522-31. [PMID: 26971341 DOI: 10.1007/s00261-016-0703-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Chernyak V, Fowler KJ, Heiken JP, Sirlin CB. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS): Use of Gadoxetate Disodium and LI-RADS. J Magn Reson Imaging 2019;49:1236-52. [DOI: 10.1002/jmri.26540] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
2 Kitao A, Matsui O, Yoneda N, Kita R, Kozaka K, Kobayashi S, Gabata T. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI. AJR Am J Roentgenol. 2018;211:347-357. [PMID: 29708786 DOI: 10.2214/ajr.17.19341] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
3 Kim YY, Kang TW, Cha DI, Min JH, Kim YK, Kim SH, Sinn DH, Won H, Kim S. Gadoxetic acid-enhanced MRI for differentiating hepatic sclerosing hemangioma from malignant tumor. Eur J Radiol 2021;135:109474. [PMID: 33352374 DOI: 10.1016/j.ejrad.2020.109474] [Reference Citation Analysis]